Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)
about
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseThe use of inhaled corticosteroids in pediatric asthma: updatePharmacotherapy in the management of asthma in the elderly: a review of clinical studiesRoflumilast: a review of its use in the treatment of COPDSearch for β2 adrenergic receptor ligands by virtual screening via grid computing and investigation of binding modes by docking and molecular dynamics simulationsInhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment ParadigmCardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?CD4(+)CD25(high)CD127(-) regulatory T-cells in COPD: smoke and drugs effectManagement of asthma and chronic obstructive pulmonary disease with combination inhaled corticosteroids and long-acting β-agonists: a review of comparative effectiveness research.Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study.Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study.Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study.Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids.Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.Predictors of exacerbations in chronic obstructive pulmonary disease--results from the Bergen COPD cohort study.Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysisSystemic effects of inhaled corticosteroids: an overview.Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia.Glucocorticoid-Augmented Efferocytosis Inhibits Pulmonary Pneumococcal Clearance in Mice by Reducing Alveolar Macrophage Bactericidal Function.Validation of an administrative claims-based diagnostic code for pneumonia in a US-based commercially insured COPD population.Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study.GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.Budesonide and fluticasone propionate differentially affect the airway epithelial barrierAssociation Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting.The risk and outcomes of pneumonia in patients on inhaled corticosteroids.The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study.Rising total costs and mortality rates associated with admissions due to COPD exacerbations.Increased risk of community-acquired pneumonia in COPD patients with comorbid cardiovascular disease.Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study.Risk of mortality and recurrent cardiovascular events in patients with acute coronary syndromes on high intensity statin treatment.Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease.Bronchiectasis: an update on current pharmacotherapy and future perspectives.Year in review 2013: Chronic obstructive pulmonary disease, asthma and airway biology.Safety considerations of inhaled corticosteroids in the elderly.Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease.Emerging drugs for bronchiectasis: an update.Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
P2860
Q24197989-0715C0F5-B04F-4F27-B0B1-4B158FF1E875Q26739763-08BC43E2-89F8-43D4-8D41-5CDAE8D304C6Q26769046-7FDFC536-6CC0-4B39-BE2A-9759CACF23D1Q26770501-B4AF0998-B76E-484D-98F6-13C067CE45A3Q27346663-710D0B92-2D1C-40FF-A31A-02F0F8A3017BQ28087788-80F0DA7D-6DBA-41B5-B3E8-34E47AAAEFD2Q28596651-464CA5FF-31FD-44C8-961C-E24D0E3CFD4CQ30390674-AD04E726-E76F-4B99-BD3C-1192F28DF947Q33646667-DCFC63C9-36CA-4CA9-A525-E68F0447BDABQ33689926-859005B3-7C6F-442F-994C-ACA6C8C8D515Q33705358-5D2353FC-00CF-48F1-B816-16F2DA2FE9A9Q33733634-B138D56D-132E-4649-95D7-6E8C26F376DFQ33803143-C6038A28-5712-4F70-92A2-AFE3125A4B61Q34065276-3284A3CD-AC7C-4DF9-AF8A-D82C7B5593ABQ34287563-819F311C-A0BD-448C-A9B9-15F383B647CFQ34551086-71BAB7E7-6F1B-4486-B891-FB88A1209438Q35056155-91DE6337-3820-48E2-9453-3C11F310012BQ35140742-FF6BA219-33A8-4E18-818E-833462FD13EBQ35538141-CDA88C1A-7DFE-4380-B8D9-7FA8405DD312Q35538249-63F4226C-FBA8-4BE1-8BA2-F6A5C94023C4Q35675040-C363A65F-812A-4233-9E48-7894D17B242AQ35762822-F513BAF6-4018-4CA0-A0C2-4B9E2CF37D25Q35892486-B1F3A5D6-08C7-45D3-AAB8-37BAB2A46E1BQ36141290-E9817B7F-C7BD-457A-9E13-8C5BC408E3F2Q36356295-695012DA-4AE3-47D1-9596-04A87856A495Q36439199-9A0E0CDB-F8C6-4D75-A14A-B71378FC7D75Q36599589-834A8C76-83B5-4977-9CE8-C37BE509FD7CQ37364624-17AE9147-788A-43C7-A85C-8A06258DF0D7Q37412962-39429C28-CFB6-4B81-B95B-A3F3A6019EB8Q37414845-5C1A29B0-71AC-4EAA-ACC5-DDB47B45BCAAQ37488835-A760719F-6844-43CC-B2B6-768593BEE1D1Q37706605-23C7537E-2DCF-48A2-AA8F-82C93BDBBC94Q37731877-8E4C5EDA-0491-4D6B-A800-1435E272A770Q38125210-703DC5DD-E2AB-44C4-AC37-3AED7F1C9966Q38177329-56CC8C26-0088-4BFB-9C41-87BCA6407117Q38202680-FC05DF5E-4ED0-4DE4-96F2-D6A064F17A5EQ38248458-A8167E26-AE9D-4EEF-B91B-5D563F130C8BQ38306695-C5F0CEF4-5ED9-44FE-99AC-04E52CCB5EC6Q38367379-068FD603-BB37-472E-8CA6-F4229431BDF5Q38550921-93960EE0-877C-42C1-8470-42AB57E7F6B6
P2860
Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Pneumonia and pneumonia relate ...... matched cohort study (PATHOS)
@en
type
label
Pneumonia and pneumonia relate ...... matched cohort study (PATHOS)
@en
prefLabel
Pneumonia and pneumonia relate ...... matched cohort study (PATHOS)
@en
P2093
P2860
P356
P1433
P1476
Pneumonia and pneumonia relate ...... matched cohort study (PATHOS)
@en
P2093
Björn Ställberg
Georgios Stratelis
Gunnar Johansson
Helena Goike
Karin H Lisspers
Kjell Larsson
Leif Jörgensen
P2860
P356
10.1136/BMJ.F3306
P407
P577
2013-05-29T00:00:00Z